Alnylam (NASDAQ:ALNY) has corrected by roughly 13% over the past couple of weeks. To understand why this pullback is unfolding now, it is important to examine the stock's structure through the lens of the Adhishthana principles and assess where it stands within its broader cycle.Alnylam's Weekly StructureOn the weekly charts, Alnylam is currently in Phase 11 of its 18-phase Adhishthana cycle. Back in July, when the stock was still in Phase 10, we published a cautious commentary titled "Alnylam Pharma Stock ...

The Nasdaq-100 Index has announced its annual reconstitution, adding six new companies and removing six, effective Dec. 22.Six Stocks Added, Six Dropped From IndexThe six companies being added to the index are: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) , Ferrovial SE (NASDAQ:FER) , Insmed Inc. (NASDAQ:INSM) , Monolithic Power Systems, Inc. (NASDAQ:MPWR) , Seagate Technology Holdings plc (NASDAQ:STX) and Western Digital Corp. (NASDAQ:WDC) .The six companies being removed from the index are: Biogen Inc. (NA ...

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?Bloom Energy Corporation (NYSE:BE) shares slumped 20.68% last week. Shares of electrical equipment companies traded lower amid overall market weakness.Credo Technology Group Holding Ltd (NASDAQ:CRDO) fell 20.09% this week. Shares of companies within the broader technology sector traded lower amid weakness in Broadcom Inc. (NASDAQ:AVGO) after it issued cautious outlook. The sector is also being weighed down by r ...

Core Insights - Alnylam Pharmaceuticals has faced challenges in the last three months due to slowing sales at a key rival, raising concerns about the overall health of the transthyretin amyloidosis (TTR) market [1] Company Summary - Alnylam Pharmaceuticals is experiencing difficulties linked to competitive pressures in the TTR space, which may impact its market position and sales performance [1]

行业研究是投资的源动力。元禾控股推出"元动力"系列行研分享，编辑部据此推出《元动力》行业研究专栏，旨在交流行业研究成果，分析行业发展趋 势，探讨未来投资方向。 本期《元动力》行业研究专栏聚焦中美生物医药投资，分享者是元禾控股研究中心（博士后科研工作站）分析师陈铭源博士，将从中美生物医药领域投资 概况、中美医疗体系的差异、"募、投、管、退"视角下的对比与思考等维度进行展开。 中美生物医药领域投资概况 美国VC投资成功案例 美国VC投资成功案例——Moderna | 成立时间 | 2010年 | | --- | --- | | 上市时间 | 2018年 | | 市值 | 1995亿美金(2021年) | | 融资信息 | 20.7亿,A轮-F轮融资 | | 核心技术 | mRNA创新药物 | | 核心产品 | mRNA新冠疫苗2022年,184亿 | | | 美元 | | 投资机构 | Flagship Pioneering解化项目 | | VC角色 | Flagship在孵化到融资阶段共投 | | | 31. 资约5000万美金,2021年所持有 | | | 7.8% 股份约有155.6亿美元 | Modern ...

Group 1: Market Overview - The Hong Kong stock market showed a collective rebound with the Hang Seng Index rising approximately 0.6%, the Hang Seng China Enterprises Index increasing about 1%, and the Hang Seng Tech Index up around 0.8% [2][3] - Market sentiment improved significantly compared to previous days, with total market turnover rising to approximately 210.4 billion HKD and the short-selling amount on the main board decreasing to about 15.74% of total turnover [2] - Southbound capital flows remained weak, with net inflows from northbound trading at around 1.3 billion HKD on Friday [2] Group 2: Sector Performance - Resource and cyclical stocks led the market rally, with rare earth, non-ferrous metals, and gold stocks performing well due to the implementation of export licenses and increased copper stockpiling by global commodity traders [3] - The financial sector also played a crucial role in driving the market upward, with insurance stocks, Chinese brokerage firms, and domestic banks generally showing strong performance [3] - Energy-related sectors, including electric power equipment, wind power, and nuclear power, were active, reflecting ongoing interest in energy transition and equipment investment opportunities [3] Group 3: Economic Indicators - The U.S. core PCE year-on-year growth rate fell to 2.8%, providing strong support for the Federal Reserve's potential interest rate cut [4] - Personal consumption expenditures in the U.S. showed almost no growth in September, indicating a cooling consumer market, with significant declines in spending on durable and non-durable goods [5] - The income distribution in the U.S. is becoming polarized, with lower-income households reducing spending while high-income groups maintain purchasing power due to asset appreciation [5] Group 4: Industry Insights - The small nucleic acid drug sector is emerging as a significant investment theme for 2026, characterized by rapid global market growth and advantages such as broad target coverage and high clinical trial success rates [7] - The global small nucleic acid drug market is projected to grow from 2.7 billion USD in 2019 to 5.7 billion USD in 2024, with a compound annual growth rate of 16.2% [7] - The market for siRNA drugs is expected to increase its share from 6.2% in 2019 to 44.5% in 2024, driven by advancements in delivery technologies and expanding indications [7] Group 5: Collaboration and Market Dynamics - The small nucleic acid field is becoming a hub for business development collaborations, with nearly 100 deals in the past three years and increasing transaction values [8] - Leading companies in the small nucleic acid market, such as Alnylam and Ionis, are setting the pace for global technological development, with Alnylam reporting a 149% year-on-year revenue increase in Q3 2025 [9] - Domestic pharmaceutical companies are also focusing on small nucleic acid drugs, with several candidates in clinical trials targeting conditions like high cholesterol [9] Group 6: Investment Recommendations - The report suggests that small nucleic acid drugs may become a major investment theme next year, with opportunities in both domestic and international markets [10] - Key companies to watch include overseas leaders like Alnylam, Arrowhead, and Ionis, as well as domestic firms like CSPC Pharmaceutical Group and Hengrui Medicine [10]

Core Viewpoint - Alnylam Pharmaceuticals is highlighted as a promising biotech stock with significant growth potential, particularly due to its innovative RNA interference (RNAi) therapies and recent product approvals [2][5][13]. Company Overview - Alnylam Pharmaceuticals was co-founded in 2002 by MIT professor Phillip Sharp, who also co-founded Biogen in 1978 [4]. - The company focuses on RNA interference (RNAi) as a novel therapeutic approach, which has gained recognition with a Nobel Prize in 2006 [5]. Financial Performance - An investment of $10,000 in Alnylam at its IPO would be worth approximately $787,000 today, indicating strong historical performance [6]. - The company's market capitalization is currently $61 billion, with a gross margin of 83.90% [9]. Product Pipeline and Growth - Alnylam received FDA approval for its RNAi therapy Onpattro in 2018, targeting a rare genetic disease, and has since launched another therapy, Amvuttra, which is expected to become a blockbuster drug [7][9]. - Sales of Amvuttra increased by 162% year-over-year in Q3 2025, showcasing strong market demand [10]. - The company is evaluating nucresiran in phase 3 clinical studies for additional ATTR indications [10]. Collaborations and Licensing - Alnylam has outlicensed its RNAi therapies, including Leqvio to Novartis and Qfitia to Sanofi, which helps mitigate risk while still generating revenue [9][14]. - The company is collaborating with Regeneron on cemdisiran and with Roche on zilebisiran, expanding its therapeutic reach [11][12]. Future Outlook - Alnylam's forward price-to-earnings ratio is 53.5, reflecting high growth expectations already priced into the stock [13]. - The company’s RNAi platform has the potential to address a wide range of diseases beyond its current focus, suggesting long-term growth opportunities [15]. - While the investment outlook remains uncertain, the company is expected to continue generating significant returns for patient investors [16].

Core Insights - Four companies identified by KBW analyst Shreyank Gandhi are among the largest not included in the index [1] Group 1 - The companies were selected from a list compiled by the analyst [1]

Core Viewpoint - The article discusses the importance of enabling Javascript and cookies in browsers to ensure proper functionality and access to content [1] Group 1 - The article highlights that users may face access issues if they have an ad-blocker enabled [1] - It suggests disabling ad-blockers and refreshing the page to proceed [1]

Core Insights - Alnylam Pharmaceuticals' stock has seen significant gains, with a year-to-date increase of 92.6% and a 58.7% rise over the last six months [2] - The company reported a strong third-quarter performance with adjusted earnings of $2.90, a notable recovery from a loss of $0.50 a year ago, and quarterly sales of $1.25 billion, reflecting a 149% year-over-year increase [2] - Alnylam raised its fiscal 2025 sales guidance to a range of $3.6 billion to $3.8 billion, surpassing the consensus estimate of $3.53 billion [3] Performance and Earnings - The adjusted earnings for Q3 2025 were $2.90, compared to a loss of $0.50 in the same quarter last year, exceeding analysts' expectations of $0.75 [2] - Quarterly sales reached $1.25 billion, significantly above the consensus of $977.79 million, marking a 149% increase year-over-year [2] - Sales of Amvuttra surged by 165% to $685.30 million [2] Analyst Outlook - Chardan Research and William Blair provided positive outlooks for Alnylam following the second-quarter results, highlighting the strong launch of Amvuttra for ATTR-CM [4] - ATTR-CM is identified as a rare and often underdiagnosed form of heart failure, indicating a significant market opportunity for Alnylam [4] Clinical Developments - Alnylam announced new post hoc analyses from the HELIOS-B Phase 3 study of Amvuttra, showing promising results [5] - A mixed model analysis indicated that treatment with vutrisiran monotherapy led to statistically significant improvements in cardiac structure and function compared to placebo [6] - At Year 3, 22% of patients treated with vutrisiran showed amyloid regression, while no patients in the placebo group exhibited this outcome [7]